Trellus Health plc

("Trellus Health", the "Company" or the "Group")

AGM Statement

LONDON, U.K. AND NEW YORK, U.S. (30 June 2025). Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces it will hold its Annual General Meeting at 1.00pm (BST) today at the Company's registered office, 201 Temple Chambers, 3-7 Temple Avenue, London, United Kingdom, EC4Y 0DT.

Kevin L. Murphy Jr., Chairman will address the meeting with the following update:

"We continue to focus on Trellus Health's key commercial verticals: pharmaceutical patient support programs, clinical trial patient recruitment and retention services, and the U.S. health plan sector. Notably, Trellus Health has recently been granted preferred vendor status by a leading global contract research organisation (CRO), and whilst not revenue generating in itself, this reinforces the value of our proprietary resilience methodology.

"Our collaborative relationship with Johnson & Johnson remains strong and we are already delivering on key early metrics of patient satisfaction ratings and engagement.

"We have continued to maintain strong discipline in our cash management and have further reduced our cost base from the average monthly burn of $500k, year to date, as announced at our annual results. With effect from August 1 2025, our average monthly cash burn will be reduced to $440k per month. This has been a focus of the Group, even as we expand our go-to-market strategy within the pharmaceutical sector. These additional reductions have extended the cash runway into mid-November 2025. The Company continues to evaluate all commercial options, including ongoing discussions with a number of potential commercial partners and discussions with professional advisers in relation to fund raising options."

Enquiries:

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

Trellus Health also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com